Hello, and welcome to today's CVS Health Q1 2024 Earnings Conference Call. My name is Jordan, and I'll be coordinating your call today. As a reminder, if you'd like to register any audio questions, you may do so by pressing star followed by one on your telephone keypad. I'm now going to hand over to Larry McGrath to begin. Larry, please go ahead. Good morning, and welcome to the CVS Health First Quarter 2024 Earnings Call and Webcast. I'm Larry McGrath, Senior Vice President of Business Development and Investor Relations for CVS Health. I'm joined this morning by Karen Lynch, President and Chief Executive Officer, and Tom Cowhey, Chief Financial Officer. Following our prepared remarks, we'll host a question-and-answer session that will include additional members of our leadership team. Our press release and slide presentation have been posted to our website, along with our Form 10-Q, filed this morning with the SEC. Today's call is also being broadcast on our website, where it will be archived for one year. During this call, we'll make certain forward-looking statements. Our forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from currently projected results. We strongly encourage you to review the reports we file with the SEC regarding these risks and uncertainties, in particular, those that are described in the cautionary statement concerning forward-looking statements and risk factors in our most recent annual report, filed on Form 10-K, our quarterly report on Form 10-Q, filed this morning, and our recent filings on Form 8-K, including this morning's earnings press release. During this call, we'll use non-GAAP measures when talking about the company's financial performance and financial condition, and you can find a reconciliation of these non-GAAP measures in this morning's press release and in the reconciliation document posted to the investor relations portion of our website. With that, I'd like to turn the call over to Karen. Karen? Thank you, Larry. Good morning, everyone, and thanks for joining our call today. This morning, we announced first quarter results that were burdened by utilization pressures in Medicare Advantage, which materially impacted our Health Care Benefit segment. We generated adjusted EPS of $1.31, which fell short of our expectations. As a result of this performance, as well as our updated expectations for the rest of 2024, we are lowering our full year 2024 guidance for adjusted EPS to at least $7. Tom will go through these results and our revised guidance in more detail. I want to start our discussion this morning by focusing on the challenges we are seeing in our Medicare Advantage business and what we are doing to address these pressures. When we last gave 2024 guidance, our outlook assumed normalized Medicare Advantage trends on top of the elevated baseline we experienced in the fourth quarter of 2023. It is now clear that the first quarter 2024 Medicare Advantage trends are notably above this level. Like others in the industry, our visibility in the quarter was impaired by the cyberattack on Change Healthcare. At the close of the quarter, we established a reserve of nearly $500 million for claims that we estimated we had not received. This represents our best estimate of missing claims, with approximately half of the reserve attributed to our Medicare business. As we closed the quarter, it became apparent we were experiencing broad-based utilization pressure in our Medicare Advantage business in a few areas. Outpatient services and supplemental benefits continued to be elevated in the first quarter and exceeded our projections. We also saw new pressures in the inpatient and pharmacy categories, some of which were seasonal or one-time in nature. April inpatient authorizations and admissions appear to have moderated. In response to these pressures, at a time when we have seen very strong enrollment growth, we implemented a series of actions to ensure our clinical operations are performing at levels consistent with our expectations. We formed multidisciplinary teams to do a retrospective review of our claims data, searching for condition-specific, geographic, or facility-based outliers, as well as to uncover any selection bias in our new and existing membership base. We ensured clinical teams are staffed for current volumes by redeploying nurses from across CVS Health and increasing hiring where necessary, and we evaluated opportunities and implemented actions to optimize our pharmacy benefit spend. In addition to those efforts, we are accelerating enterprise productivity initiatives to streamline and optimize our operations, ensuring our costs are aligned to the business operations, environment, and conditions. We are implementing these actions with speed and urgency, utilizing the broad resources and experience across CVS Health. We have a track record of successfully navigating complex industry pressure, and we'll continue to demonstrate our resilience. We'll provide updates throughout the year on these efforts. I also feel it is important to discuss our long-term outlook for Medicare Advantage. We recently received the final 2025 rate notice, and when combined with the Part D changes prescribed by the Inflation Reduction Act, we believe the rate is insufficient. This update will result in significant added disruption to benefit levels and choice for seniors across the country. While we strive to deliver benefit stability to seniors, we will be adjusting plan-level benefits and exiting counties as we construct our bid for 2025. We are committed to improving margins. Despite the recent challenges in Medicare Advantage, we firmly believe the program can remain a compelling offering for seniors and a very attractive business for Aetna and CVS Health over time. Medicare Advantage will continue to deliver significant value to members, as well as better outcomes and patient experiences. Over the next few years, we are determined to improve our positioning in Medicare Advantage. The combination of our internal efforts and the multiyear repricing opportunity gives us confidence in our ability to return to our target margins of 4%-5% in 3-4 years. Our top priority in the near term is addressing the pressures faced by our Medicare Advantage business. However, I urge you not to lose sight of the power of our enterprise. The strength and diversity of our business positions us for growth in 2025 as we deliver value to our patients, customers, and shareholders. We are ensuring a viable biosimilars market in the U.S. with our Cordavis business, which will drive lower costs for our customers, savings for consumers, and will lead to higher retention and growth. On April 1, we implemented our unique and meaningful formulary change related to Humira. We have already made a significant impact in the first month since the formulary change, dispensing more biosimilar Humira prescriptions than the entire U.S. market in 2023. This accomplishment truly highlights the combined strength of our CVS Caremark, CVS Specialty, and Cordavis businesses to accelerate biosimilar adoption and our commitment to customers to lower pharmacy costs. Our Pharmacy and Consumer Wellness business delivered strong performance this quarter, highlighted by our ability to grow pharmacy share despite softening consumer demand and an uncertain macroeconomic environment. Our CVS Pharmacy locations continue to serve an important and expanding role in communities across the country. Since we unveiled CVS CostVantage and TrueCost, we have seen a tremendous interest in these more simple and transparent pharmacy models. We are engaged in active discussion with PBMs to roll out CVS CostVantage for commercial contracts on January 1, 2025. Additionally, we signed CVS CostVantage agreements with multiple third-party discount card administrators that were effective on April 1 and represent more than 50% of all CVS discount card volume. We continue to have constructive dialogue with our partners and look forward to updating you later this year. In our Health Care Delivery business, we are seeing meaningful progress in our integration efforts. This quarter, Signify Health had the highest volume of in-home evaluations in their history. Oak Street Health at-risk patients grew nearly 20% over the same quarter last year, supported by our ability to utilize touchpoints across CVS Health. In Aetna, our commercial business had several wins with large group clients with 2025 effective dates, demonstrating our ability to deliver integrated benefit solutions with our diversified portfolio of offerings. In our Medicaid business, we have been successful in several RFPs, including Virginia, Michigan, and Texas, where our CVS Health assets were highlighted as differentiators. These represent a few recent highlights from across our businesses and demonstrate the value and positive momentum across our broad-based portfolio of assets. The current environment does not diminish our opportunities, our enthusiasm, or the long-term earnings power of our company. We are confident that we have a pathway to address our near-term Medicare Advantage challenges. While recent results have been pressured, our actions will return our earnings to their appropriate levels and will result in a stronger CVS Health. We remain as committed as ever to our strategy and believe that we have the right assets in place to deliver value to our customers, members, patients, and our shareholders. Tom will provide details on the results of each of our businesses and the components of our updated guidance. Tom? Thank you, Karen, and thanks to everyone for joining us this morning. In the first quarter, our revenues were approximately $88 billion, an increase of approximately 4% over the prior year quarter. We delivered adjusted operating income of approximately $3 billion and adjusted EPS of $1.31. We also generated cash flow from operations of $4.9 billion, a lower result compared to the same quarter last year, primarily due to the timing of Medicare payments. Each of our segments in the enterprise as a whole are focused on executing against their goals and delivering on their financial targets. However, our Health Care Benefits and enterprise results are being materially pressured by the level of Medicare Advantage utilization that we are experiencing. Clearly, this is a disappointing result for us. Let me walk you through some of the drivers and help you understand how we expect them to impact the remainder of the year. In our Health Care Benefits segment, we delivered revenues of approximately $32 billion, an increase of approximately 25% year-over-year. Medical membership was 26.8 million, up 1.1 million members sequentially, reflecting growth in Medicare, individual exchange, and commercial group products, partially offset by the impact of Medicaid redeterminations. Adjusted operating income for the first quarter was $732 million. This result reflects a higher medical benefit ratio, partially offset by higher net investment income and the impact of favorable fixed cost leverage due to membership growth.... Our medical benefit ratio of 90.4% increased 580 basis points from the prior year quarter, primarily reflecting higher Medicare Advantage utilization, the premium impact of lower Star Ratings for payment year 2024, and unfavorable prior year development as compared to the prior year. Digging into the drivers of Medicare Advantage cost trends, we saw meaningful increases in utilization. We continue to see elevated trends in the same categories we discussed at the end of 2023, including outpatient and supplemental benefits, categories that appeared to be moderating earlier in the quarter, but which completed at levels that in some cases exceeded expectations. Adding to the outpatient and supplemental benefits pressure, we saw new pressures emerge from inpatient categories, RSV vaccines, and other pharmacy benefits. Inpatient admits per thousand in the first quarter were up high single digits versus the first quarter of 2023. While a portion of this increase was anticipated because of the implementation of the Two Midnight Rule, this result meaningfully exceeded our expectations for the quarter, as inpatient seasonality returned to patterns we have not seen since the start of the pandemic. In our Medicaid business, we experienced medical cost pressures, largely driven by higher acuity from member redeterminations. We are working closely with our state partners to ensure the underlying trends are reflected in our rates going forward. Medical cost trends in our commercial business have not shown the same pressures we are experiencing in Medicare. Inpatient bed days are favorable to expectations, although higher than prior years. Mental health and pharmacy trends remain elevated, but overall performance of the commercial block is consistent with our projections. Individual exchange medical costs are elevated but are consistent with projected membership mix and lower revenue payables in 2024. Our individual exchange business remains on target to achieve its profit goals this year. We will continue to monitor both of these blocks closely, but their performance to date is consistent with our prior projections. Days Claims Payable at the end of the quarter were 44.5 days, down 1.4 days sequentially. This decrease is primarily driven by the impact of membership growth and higher pharmacy trends, which tend to complete quicker and reduce DCP, as well as other typical seasonal items. Premiums and reserves both grew sequentially, approximately 20%. As a reminder, DCP is an output of our reserving process, and overall, we remain confident in the adequacy of our reserves. In early April, we saw multiple days of high paid claim activity, which is consistent with the restoration of Change Healthcare and the associated backlog from that disruption. While the final impact of the Change Healthcare disruption will not be known for several months, our most recent interim reporting suggests that our March 31st reserve balances are stable and could show modest levels of positive development, which is not incorporated into our current outlook. Our Health Services segment generated revenue of approximately $40 billion, a decrease of nearly 10% year-over-year, primarily driven by the previously announced loss of a large client and continued pharmacy client price improvements. This decrease was partially offset by pharmacy drug mix, growth in specialty pharmacy, and the acquisitions of Oak Street Health and Signify Health. Adjusted operating income of approximately $1.4 billion declined nearly 19% year-over-year, primarily driven by continued pharmacy client price improvements, lower contributions from 340B, and a previously announced loss of a large client. This decrease was partially offset by improved purchasing economics. Total pharmacy claims processed in the quarter were nearly 463 million, and total pharmacy membership as of the end of the quarter was approximately 90 million members. We continue to drive growth in our Health Care Delivery assets. Signify generated revenue growth of 24% compared to the same quarter last year. Oak Street ended the quarter with 205 centers, an increase of 33 centers year-over-year. We continue to expect to add 50-60 centers in 2024. At-risk members at Oak Street ended the quarter at 211,000, an increase of 34,000 year-over-year. Oak Street also significantly increased revenue in the quarter, growing over 25% compared to the same quarter last year. In our Pharmacy and Consumer Wellness segment, we generated revenue of approximately $29 billion, reflecting an increase of nearly 3% versus the prior year and over 5% on a same-store basis. Drivers of this revenue growth in the PCW segment included increased prescription volume with increased contributions from vaccinations, as well as pharmacy drug mix. These revenue increases were partially offset by the impact of recent generic introductions, continued reimbursement pressure, a decrease in store count, and lower contributions from OTC test kits. Adjusted operating income was approximately $1.2 billion, an increase of approximately 4% versus the prior year, driven by increased prescription volume, improved drug purchasing, and lower operating expenses, including the impact of store closures. These increases were partially offset by continued pharmacy reimbursement pressure. Same-store pharmacy sales were up over 7% versus the prior year, and same-store prescription volumes increased by nearly 6%. Same-store front store sales were down by about 2% versus the same quarter last year, but up 1% when excluding OTC test kits. As a reminder, the public health emergency was still active during the first quarter of last year. Shifting to liquidity in our capital position. First quarter cash flow from operations was $4.9 billion. We ended the quarter with approximately $1.9 billion of cash of the parent and unrestricted subsidiaries. In the first quarter, we returned $840 million to shareholders through our quarterly dividend. We also completed our $3 billion accelerated share repurchase transaction, retiring approximately 40 million shares in the quarter. We do not expect to repurchase any additional shares for the remainder of 2024. Our leverage ratio at the end of the quarter was approximately 4 times. This leverage ratio was higher than we expect to maintain on a normalized basis. We remain committed to maintaining our current investment grade ratings. Turning now to our full year outlook for 2024. As Karen mentioned, we revised our 2024 Adjusted EPS guidance to at least $7 to reflect our first quarter results, as well as our updated expectations for the remainder of 2024. In our Health Care Benefits segment, we now expect adjusted operating income of at least $3.6 billion, down from our previous guidance of at least $5.4 billion. We now expect our 2024 medical benefit ratio to be approximately 89.8%, an increase of 210 basis points from our previous guidance. In the first quarter, Health Care Benefits medical costs, primarily attributable to Medicare Advantage, came in approximately $900 million above our expectations. If we break that down further, we estimate that roughly $500 million of that variance is specific to the quarter or seasonal, including the larger than expected impact of seasonal respiratory and RSV costs, and a return to inpatient seasonality patterns that look much more like pre-pandemic periods. As Karen mentioned, early indicators for April inpatient authorizations support our current seasonality projections and their return to pre-COVID patterns. We've also raised our expectations for RSV-related costs in the second half based on our experience in the first quarter. The remaining approximately $400 million of medical cost pressure in the first quarter is driven by elevated utilization trends that our guidance now assumes will persist for the remainder of 2024. The primary drivers of this projected variance include outpatient service categories such as mental health and medical pharmacy, as well as supplemental benefits such as dental. Partially offsetting some of this pressure is better than expected volumes, expense management, and increased net investment income, which together are expected to contribute approximately $500 million more than we assumed in our previous full year guidance, with roughly half of this offset occurring in the first quarter. In our Health Services segment, we are updating our estimate for 2024 adjusted operating income to at least $7 billion, a decrease of approximately $400 million. The majority of this adjustment is attributable to Health Care Delivery, predominantly in our CVS Accountable Care business, driven by Medicare utilization and some out-of-period pressure. We also saw some modest utilization pressure at Oak Street during the quarter and are including a provision for higher trends for the remainder of the year in our updated guidance. The remainder of the pressure is in our other businesses in the Health Services segment, primarily driven by volume and mix trends, and the associated impact on our ability to deliver on network and client guarantees. Our expectations for the Pharmacy and Consumer Wellness segment remain the same, with adjusted operating income of at least $5.6 billion. This outlook incorporates a cautious stance on consumer activity over the remainder of the year due to slowing front store activity in the first quarter. We now expect 2024 share count to be approximately 1.265 billion shares, and our adjusted tax rate to be approximately 25.6%. Finally, we updated our expectation for cash flow from operations to at least $10.5 billion in 2024. You can find additional details on the components of our updated 2024 guidance on our investor relations webpage. We plan to share more detailed 2025 guidance later this year, but in an effort to help investors build reasonable expectations for next year, we wanted to share some preliminary thoughts on our outlook. Within Health Care Benefits, our Medicare Advantage business is projected to generate between $65 billion and $70 billion in revenues in 2024, but will experience significant losses. We are committed to driving meaningful improvements in our Medicare Advantage margins in 2025. Given our projected baseline performance, 2025 will be the first step in a 3- to 4-year journey to get back to our target margins of 4%-5%. Improved Star Ratings in 2025 could represent a $700 million tailwind, depending on membership retention levels, but also reduces our ability to adjust certain benefits. The remainder of our margin improvement in 2025 will be a function of pricing actions in an environment where we are facing headwinds from an insufficient rate notice and prescription drug coverage changes that substantially increase plan liability. We will take material pricing and benefit design actions for 2025, and the impact of those changes will depend on how cost trends develop in both 2024 and 2025, and how the market responds to those trends. In Health Care Benefits other business lines, we are building strong momentum. We are planning for another year of margin progression in our individual exchange business. We've seen success in the group commercial selling season this year, and we're recently awarded several key Medicaid RFPs. In our Health Services segment, early progress of our Cordavis business is encouraging and supports our innovative approach to the biosimilar opportunity, driving differential savings for our PBM customers. In our H ealth Care Delivery business, we are committed to improving margins in CVS Accountable Care. Oak Street's margin trajectory will be supported by meaningful patient enrollment and a realignment of Medicare Advantage benefits as the market adjusts to elevated utilization. Signify continues to show impressive growth and is building momentum into 2025. We have received a strong early reception to our new pharmacy model, which creates potential for outperformance in our PCW segments. As Karen mentioned, we are accelerating multi-year enterprise productivity initiatives to streamline and optimize our operations. Finally, our framework contemplates a stable share count in 2025. While many uncertainties remain, that could drive a wide range of outcomes, including our 2024 baseline performance and the potential that medical cost trends subside as compared to our current outlook. At this distance, our goal remains to deliver low double-digit adjusted EPS growth in 2025. Our team remains committed to executing against opportunities to outperform this guidance. With that, we will now open the call to your questions. Operator? Thank you. As a reminder, if you'd like to register any audio questions, please press star followed by one on your telephone keypad. If you change your mind, please press star followed by two, and please ensure you're unmuted when speaking. Our first question comes from Justin Lake of Wolfe Research. Justin, please go ahead. Thanks. Good morning. A couple of questions here. First, on the cost trend in the first quarter. Would like to get some more detail on the $500 million that you said is in Q1, that's not going to reoccur, right? I think everyone would like to get comfort that, you know, this $7 is a baseline that we can be comfortable with. So if that's not reoccurring, can you just walk us through what the moving parts are there? For instance, you know, it looks to me like your PYD was $200 million below the last couple of years. Maybe that's a big part of, y ou know, that's clearly a big part of it. How much was RSV, any other moving parts, anything you could do to get us comfortable that that $500 million is, you know, seasonal would be, would be a good start? Hey, Justin, it's Tom. So, the largest impact within that, within the quarter is, the seasonality adjustment on inpatient. And as I noted in the prepared remarks, our April authorization data supports our updated seasonality projection, as we did experience some negative prior year development in the quarter, and that is clearly part of the $500. But as you look at where that occurred, that was really in some of our inpatient categories where the trends restated negatively. And so you saw the beginning of that uptick, you saw an uptick again, January admits were higher than our expectations. February was improved versus January, March was improved versus February. And so we've seen really we saw a spike earlier in the quarter, which, and, you know, which really started, you know, in hindsight, in the fourth quarter. And as you look at that pattern, it very closely resembles what we would have seen in, you know, a 2018, 2019 period trended forward. And so, you know, that gives us a lot of comfort as we look at both what we're seeing now, versus, well, what the historic patterns pre-COVID look like, that a lot of this was actually seasonal. So if you take out the prior period development, you also had some provider liabilities that were settled inside the quarter. As we did have some policy liberalizations that took place, inside the quarter, and they've been reinstated since the quarter end, so that should not be an ongoing impact. And then there were some other one-time impacts, including the initial reserve build for some of our new membership growth, that would be incorporated inside that $500 million. We also, as you noted, we did see some RSV in the quarter. We did make a revision for some of those costs of the $500 million to recur in the back half of the year, but we're not projecting that the vast majority of those costs are going to be part of the run rate, unlike the $400 billion that we're pulling through. Got it. And then just some color on the Medicare Advantage margin and improvement in any offset. So right now, it looks like if I estimate your MA margins, I'm thinking -3 to -4% negative. Is that the right ballpark? How much of an improvement, y ou said material improvement, you know, that would seem, you know, if you got a couple of hundred basis points there, by my estimate, that's, you know, $0.70-$0.80 alone. So can you talk us through how much improvement would you think is material to get back, you know, that trajectory to the, you know, over 3-4 years, and anything that would be an offset there, any kind of one-time benefits this year, like, you know, bonuses, things like that, that would work against it would be helpful. And I'll jump out of the queue. Thanks. Yeah, Justin, great question. So as you think about Medicare Advantage, you know, as I said, it's a $65 billion-$70 billion revenue portfolio today, and our goal for next year is that we would get about 200 basis points of margin improvement in that business or up to that amount. And we obviously haven't finalized our bids yet. You know, you're in the probably the right ZIP code as you think about what the margin is on the Medicare or implied margin is on the Medicare business. As you think about that business, we talked last quarter about the fact that it was gonna be break even in our current projections, and you know, we lowered the guidance in Health Care Benefits by $1.8 billion, and so the majority of that is related to Medicare. So, you know, we've given you all the pieces to kind of understand why we think it'll lose a significant amount of money this year. But as you think about improvement there, obviously, there's a lot of work that we still need to do to understand what benefits we're going to adjust and, you know, what ones we can and can't. Our Stars, is a tailwind, but also impacts our ability to adjust, because it lowers our TBC, availability on that national PPO contract. And maybe, Brian, do you wanna give a little bit of color how you're thinking about bids and margin improvement? Sure. Thanks, Justin. So I, I would talk about 2025 in terms of headwinds and tailwinds, and let me just walk through those. So obviously, we have very significant high trend that we are absolutely going to incorporate into our pricing, and so the trends that Tom talked about for 2024, we will reflect again in 2025. So that's clearly a headwind, but we're not gonna miss on trend. We've talked in the past about the Part D changes, which is a really important element here, and there's really two elements of that. One is that the benefit has been enriched pretty significantly by the IRA. And then secondly, the plan is on the hook for a greater liability in the catastrophic layer, and that we get less reinsurance than we used to, and so we intend to price for that and be very thoughtful around that. Third, as we've, you know, Karen mentioned in her remarks, the rates that we received were clearly disappointing and not sufficient to make up the trend pressures and IRA pressures that we're seeing. And then finally, as Tom mentioned around TBC, that's clearly a limitation that we need to be focused on. It's focused on the general enrollment block. It does not apply to D-SNP, and it does not apply to certain supplemental benefits as well, which we'll be very focused on to make sure we rightsize for 2025 pricing. As we think about tailwinds, though, Tom mentioned the Star Ratings tailwind, which is about $700 million, assuming a stabilized membership, and I'll come back and talk about that a little bit. With respect to the pricing actions, we're gonna be very focused on taking those pricing actions, as I mentioned, to incorporate the trends, but also be mindful of how we think about TBC. Star Ratings does impact TBC in that it reduces the amount of allowance we have under the regs. But as I mentioned, there are opportunities we have to trim benefits around TBC, and we'll be very focused on doing that. On the D-SNP product, our intention is to reduce our supplemental benefits in certain areas, including some of the flex cards that we put in the market this year. And so you'll see us reduce those benefits, and that allows us to capture margin, without impacting TBC, and so that's important. The other point I'd make, and Karen and Tom alluded to it, we will be taking actions around certain service areas. So to the extent that we don't believe we can credibly recapture margin in a reasonable period of time, we will exit those counties. We will also be looking at areas where we believe that it makes sense to actually discontinue a specific product, then reintroduce a new product, where TBC won't apply, and we'll be looking at those opportunities as well, being mindful of the member disruption and some of the churn that you might see. And so as we step back, we are very focused on margin, margin over membership. Obviously, we're trying to create a stable book with respect to our membership. As we think about the membership impacts, I think there are several things that go into that calculation. One is we believe there will be significant disruption in the PDP market and the Med Supp market. We're gonna see prices go up, we're gonna see people exit certain plans, and we know prices are increasing on Med Supp, and so that'll be a tailwind to our membership projections, offset by the fact, as I mentioned, as we've all mentioned, that we're gonna be taking significant pricing actions, and really, it's going to depend on what our competitors do. We believe that they're rational. We believe they're seeing similar type trends, and so they're gonna price as well for some of these pressures, but that's something that we'll have to calibrate as we get into pricing, and as I mentioned, there will be some service area reductions. But again, the focus is on margin over membership. If there's a membership reduction, it's relatively small, impacts on margin, and we're focused on making sure we price this product appropriately for 2025 and beyond. Yeah, Justin, I'm just gonna reiterate what I said in my prepared remarks. We are committed to improving margin in Medicare Advantage, and we will do so by pricing for the expected trends. We will do so by adjusting benefits and exiting service counties, and we are committed to doing that. Our next question comes from Lisa Gill of JP Morgan. Lisa, please go ahead. Thanks very much. I just wanna follow up on a few things that you said. Brian, I wanna go back to your comment around membership and your expectation that the decline in Medicare Advantage membership could be small. Is that based on assumption that the pressure we're feeling, it's for everybody in Medicare Advantage, and that therefore, everyone will readjust? And again, to Karen's point, you'll look at certain counties and adjusting certain plan levels, so you could lose some membership, but you're not expecting a large membership decline, as you think about 2025, just with the increased cost and, you know, changing benefits, et cetera. I just wanna make sure that I understand that to start. Sure. And thanks for the question, Lisa. So I would say there are two elements here. There's the, what's gonna happen from an industry perspective and growth, and then what we at Aetna are gonna do. So on the industry side, as I mentioned, I think there are some clear tailwinds from the perspective of of what's gonna happen in the traditional fee-for-service market, i.e., PDP and Med Supp. And so as members, potential members are evaluating their choices, they're gonna have to take a look at what are the price increases and some of the disruption that's gonna happen in the traditional fee-for-service market. So that that would be a tailwind. I do think, though, that the industry broadly is going to be trimming benefits, in some cases significantly, and exiting from certain, certain counties that aren't profitable. I think that's an industry issue, and I think it's clearly an Aetna focus as well. And so how that calibrates, where we ultimately end up on membership, is something that, again, we gotta work through bids and pricing to sort of estimate what we think our competitors are gonna do. So it's hard to say right now that we won't have a meaningful decrease in membership. It's certainly possible. What the message we're trying to communicate is, we're focused on margin over membership, and to the extent that we do have a larger than desired membership reduction, then that will, that will occur, and we'll focus on the margin side. But again, I think our competitors here are rational. I think they are facing a number of similar pressures. Obviously, we have our own unique elements that we need to address as well. And so I think that calibration, as well as what happens to the broader industry, will really dictate where membership goes next year. Hey, Lisa, just, as you, from a very high level, as you think about what the impact of membership loss is, just, you know, think about the comments that we made about margin restoration relative to the implied, you know, losses in the book. And so losing additional members doesn't necessarily contribute to lost profit in 2025. And then, Tom, if I can just understand the cadence of 2024, and you know, you obviously talked about low double-digit growth in 2025. How do we think about that cadence as we're continuing throughout 2024? Anything you would specifically call out as we think about the rest of 2024? Yeah, you know, one of the things that I think is worth talking a little bit about, as you think about the Health Services segment, you know, we do have some pressures in there that we think are Medicare market related in the Health Care Delivery business. We also saw, you know, some timing and mix-related impacts in our other Health Services segment businesses. And we've taken a cautious stance right now on in-year recovery on those, you know, and that's because, you know, we lost a large client there. We had some insourcing activity at another large client. We've had some supply shortages in some other categories. We also delayed the initial launch of our biosimilar product to April first from our initial plans, you know. So accordingly, as we look at the seasonality of earnings, we think, you know, we currently expect that you'll see probably more like 55%-60% of our earnings in the second half of 2024, to adjust for some of that sloping. Okay, great. I'll stop there. Thanks. Our next question comes from Nathan Rich of Goldman Sachs. Nathan, please go ahead. Great. Good morning, and thanks for the questions. I just wanted to follow up on some of the drivers for 2025. You know, I guess from, from this, this point in the year, I mean, can you talk about, you know, how big of a shortfall the final rate was relative to what your current view of kind of cost trend will be for 2025? And then how are you thinking about the change in profitability for the Part business and Part D business next year in light of the benefit design changes that you've talked about? I might leave it to Brian to talk about the Part D changes and their impact on profitability. You know, there is a very substantial change in plan liability there, which will result in much higher premiums, which we think is gonna impact, you know, both overall benefits within the bids, but also, as we think about those seniors that are currently, you know, in the market to purchase a bundle, that the cost of that bundle is going to rise pretty dramatically for them, which may, even with a less robust set of benefits, make Medicare Advantage an attractive option in 2025. You know, the bid itself for 2025, what we received from CMS, the pricing was just disappointing. It's, you know, clearly, as we look at our trends, as we look at the market trends, we don't think that the rate sufficiently reflects that. We have another year of the phase-in of the risk adjustment model. There's no flexibility that's been given to date on on TBC, despite the material changes that we are experiencing because of the Inflation Reduction Act on Part D. And so, you know, the combination of those things just makes a tough year for 2025 pricing harder, when we don't see the pull-through of what most of the market participants are experiencing into, into the bid baseline. And Brian, maybe you could talk a little bit more about that. Sure. I mean, first, with respect to Part D, I think Tom articulated it well. There's just, you know, incremental benefits that are being offered and, you know, significant increase in plan liability. And while there'll be an increase in direct subsidy, and we're expecting that, it really isn't sufficient to cover that increased liability that the plans have. And so there's gonna be a lot of discussion, I imagine, in the industry, certainly here at Aetna, about what product is ultimately viable for, for us, as we think about the potential risks and volatility that could result from putting out a product, and the impact of potential adverse selection in terms of who you attract. The types of members you use, brand utilizers, specialty utilizers, et cetera, creates additional uncertainty, particularly because of that enhanced liability and the fact that the benefits are so rich that typical, you know, traditional views of insurance and, you know, getting low price and those sorts of things may or may not apply in the same way as it did. And so those are the types of things we're thinking through. And obviously, as we, you know, come back on the next quarter call, we'll give you more color about our perspective on, on the Part D market. We do think there's gonna be disruption. We do think it's gonna necessitate premium increases, and that's why there's just some uncertainty about where the ultimate industry goes from an MA perspective in terms of membership. With respect to your first question on the trend delta, look, it's obviously very significant. You know, we've been very clear that the trends that we're seeing in 2024, which are really consistent with 2023, we expected some measure of break to a more normalized trend, as Karen and Tom said. And frankly, I think we were conservative on what a normalized trend would be. If you go back historically, even before the pandemic, for many, many years, trends were in the 3%-5% range. We saw trends in 2023 approaching 10%. We're seeing trends in 2024 mirror those levels, exacerbated even more so by some of the seasonal factors that Tom mentioned in the first quarter, and so we're gonna continue those trends into 2025. Now, we have really not seen 2 years, let alone 3 years of those levels of elevated trends without break, but it's imperative that we include that in our pricing, and we intend to do that. Our expectation is, our competitors will be thinking about it in a similar fashion. So we need to think hard about how we're gonna make up that delta between what we got in the pricing and what we got in trend, what we have in trend, and there are a number of levers we're gonna pull, benefits is one that clearly we're gonna be focused on. Great. And if I could just ask- Nate, as I just think about stepping back from your question- Yeah. As I just think about stepping back from your question, Nate, you know, revenue in that product per member is clearly gonna go up. It's just not clear exactly what's gonna happen to the overall membership base, but we're gonna price for a profitable product and what's ultimately gonna be a higher premium product on Part D. Okay, great. And sort of where I wanted to go with the follow-up, you know, you talked, Tom, about the 200 basis points of margin improvement in the MA business next year. So, you know, that's around $1.3-$1.4 billion, depending on where membership shakes out, and half of that's the Stars tailwind. I think if, you know, we just look at the other, you know, $700 million on a PMPM basis, it's $10-$15 PMPM. But it sounds like there may be some cost headwinds that are maybe offsetting the, you know, change in benefits. And so I guess I wanted to see if you could give us a rough sense of maybe the type of reduction that you're talking about in terms of the benefit design as we think about next year, and then what the opportunity would be, you know, as we think three or four years down the road. Yeah, Nate, I think for competitive reasons, I don't wanna get into any more than we've already given relative to the improvement or any more granularity there, other than to say, you know, I, I think we've made it clear that everything's on the table. You know, so there are TBC benefits that will probably get adjusted. There are non-TBC benefits that will get adjusted. We'll look at, you know, all—like, this is, this is not an acceptable result where we're gonna be for this year in terms of profitability on this block of business. And so, you know, we're gonna look at everything that we can do, to try to improve profits for next year, and maintain some level of stability inside the book. As you're doing the bridge between 2024 and 2025, there are some variable expense items that are clearly gonna come back in 2025. That's part of the reason that we've talked about how we're gonna accelerate some of our expense efforts to try to offset any restoration of expense that would come back in 2025. It's a little early days to you know to try to talk about what that will, that will yield in 2025, but we're committed to taking action to help offset any headwinds there. And we'll give you more updates on that as we get to next quarter. Yeah, Nate, I would just add that, you know, we continually evaluate our overall cost structure with respect to operations, process, productivity, and, you know, we began a comprehensive review of that last year. We took actions. They're showing up this year, and now we're going to accelerate, you know, other initiatives over the next few months. And as we continue to size those efforts, we'll update you throughout the year. Our next question comes from Stephen Baxter of Wells Fargo. Stephen, please go ahead. Yeah, hey, another follow-up on Medicare Advantage. Thank you. You mentioned in prepared remarks that I think you spent time looking for potential selection bias, either with new members or inside of your existing book. I'm not sure if you talked about what you actually found when you did that, so just trying to understand whether you saw, you know, greater than expected switching from your own members, or if the step down in profitability across the broader book was mirrored in your new membership, or maybe that was something in excess of that to consider. Thank you. Yeah, so we've looked at it very closely, as you can imagine, trying to understand whether the new members are creating a disproportionate impact on our results. And we've analyzed it every which way we can. And when you look at basic results, such as their admissions per thousand, or their pharmacy spend, or their risk score, or other categories of care, we're really not seeing a material difference between the new members and the old members. And so what we're really seeing is a pressure on our entire book that that you know we are have you know having to take action against ultimately. You know, we looked at things, of course, and I know there's been a lot of discussion around the fitness benefit, for example. That was clearly something that was appealing to our members on the general enrollment block. It's just on the general enrollment block in terms of selecting that benefit. When we look at the financial impact of that, actually it's pretty modest. It's actually running in line with our pricing expectation. Some of the dental benefit enrichment that we did, we are seeing some pressures, as Tom mentioned, on that supplemental benefit. We are seeing more members use that benefit and use more of it, and so but that's really across- ... the book. And so again, I don't see a selection bias between old and new members, but rather pressures throughout that we need to address for 2025. Our next question comes from Michael Cherny of Leerink Partners. Michael, please go ahead. Good morning, and thanks for taking the question. Maybe I'll stick to Health Services for a second. I'm sure others can come back with other M&A questions. But as you think about the performance in the quarter and the dynamics you're seeing about prepping, both for changes in members, changes in the customer losses, how in terms of the large customer roll-off, how do you think about the scaling dynamics of your purchasing capabilities and how that's ramping into Cordavis as you've launched that? And I guess you gave us an early look there, but are there any additional signs you can give us on how you think about the financial contribution of Cordavis baked into either this year's guidance or in terms of the targets for next year? There, there is a contribution from Cordavis that's embedded in our Health Services guidance. We haven't disclosed to date, Michael, what that impact is, other than to say, you know, versus our initial projections, because we delayed the formulary change to four one, we had hoped to do it a little earlier in the year. That did have a little bit of a timing impact inside the quarter, but, you know, the adoption there has been fabulous. The client reception has been fabulous, and, maybe, David, you could talk a little bit more about what you're seeing there. Sure. Thanks, thanks, Tom. And before I get into the actual results for, for the biosimilar change, maybe I'll just spend a second talking more broadly about, the question you asked around control and kind of our confidence on the ability to continue to have purchasing advantages in the market. And so I go back to the strength that we have in specialty. So most of all the success we've delivered is because of our leadership position, specifically in the specialty marketplace. So we have unmatched access, both across mail, retail, and in the home infusion space. And we have broad set of products, both in the pharmacy and the medical, benefit side. Continue to be a leader in the limited distribution category, continue to be a leader in the new developing cell and gene therapy marketplace. So that, combined with the technology that we've invested, has allowed us to be kind of a leading provider in this space. So that is the foundation, allowed us to have the confidence to make the change for the formulary position on on April first. So if you look at what was mentioned in the, in the prepared remarks, we've actually had a change as of April 1, removing Humira from the formulary, and replacing it with a low list priced biosimilar. And as we said earlier, in just three weeks time, we've actually surpassed all the biosimilar volume in all of 2023. So that's. We've been able to hit what is important in terms of control and in towards the purchasing, which is that we've been able to migrate more than 90% of the volume in the first month. And then when you look specifically inside the CVS Specialty pharmacy, where we had a set of new services around technology, access to the prescribers and the members, we've been, we've actually had a 94% conversion rate. So it's a really powerful outcome, and I think it speaks to, obviously, the strength of our business. And as that translates into savings for our customers, we had mentioned that we're delivering a 50% savings on the 2022 run rate for this drug. And then as you translate that into the member benefits, because we've actually moved to the low list price product, and we've actually had clients adopt what we would call an intelligent benefit design, we've been able to have 80% of the members with a $0 out-of-pocket. So again, I think if you look at what we've done, it's a clear win for our clients, our patients, and we've also made a considerable investment in the durability of the biosimilar market. So I think all of that then contributes to the question you originally asked, which is, size and scale really is generally driven. And what I would believe, the strength in our purchasing economics is the ability to control and move market share. And again, this is another evidence in the market that we hope to continue down that path. Yeah, and Mike, I would just say on the biosimilar, you know, obviously it represents one of the biggest opportunities to reduce overall pharmacy costs, for the U.S. Health Care System. As you know, it's a $100 billion market by 2030, and as you can see, in the very first few weeks of our launch, we've had, incredible adoption, and we continue to evaluate the pipeline of opportunities. So we are excited about, the potential in the future of the biosimilar market. Our next question comes from Josh Raskin of Nephron Research. The line is yours. Hi, thanks. Good morning, here with Eric as well. So my question is that. Well, first, just numbers question. The $400 million in Health Care Services Guidance Reduction, how much of that is specifically Oak Street? And then on the MA, I hear still committed to 4-5. The journey starts in 2025. That's very, very clear. How much of your membership is in counties that you're contemplating exiting, just, you know, sort of wholesale leaving of the, of the market? And then also, how does the repricing of MA fit into your overall enterprise strategy, as, you know, obviously lots of your assets sell into that channel as well? Let me, let me start with the HSS question, Josh, and then we can, we can try to get to the other ones. So as you think about HSS, so we took it down by about $400. The majority of that reduction is the Health Care Delivery business, and the largest driver in there is unfavorability on CVS Accountable Care that came through in terms of the savings rate, which is driven by, you know, Medicare utilization, and that includes an out-of-period charge that was taken in the first quarter that's embedded in there. You know, I'd say the remainder of that, you know, that piece of a piece is is really Oak Street. But as we think about the first quarter, the performance in that business was reasonably good. And so, as we think about, though, what we've seen in the broader market, we made a provision that, you know, perhaps there could be some lag there in our forward outlook. We'll obviously have to see how that ultimately develops. As you think about 2023, the business did an excellent job of navigating some of the broader headwinds in the marketplace with some of their new clinical programs and, you know, how they played out over the course of the year. We're hopeful that we could see some, you know, some favorability to that number over time, but we have to see how that all manifests itself in the results. Mike, I don't know, anything else that you would add? Yeah, Tom, I think you summed it up well from a financial perspective. And the thing I would add when I think about Health Care Delivery more broadly, and specifically Oak Street, is for the rest of 2024, and really in 2025 and beyond, I think there's a huge opportunity that Brian and I are working really closely on, on how do we leverage the quality of care and the ability to really bend medical cost trend and drive MLR improvements. How do we leverage that more broadly across Aetna with Oak Street? And so there's a lot of things we're doing, both from adding membership from Aetna to Oak Street centers, but also leveraging some of the out-of-center capabilities we have around transitions programs and care in the home that we use for Oak Street today. Let's use that for more Aetna members. So I think there's a lot of opportunity here that we'll see play through in the coming years. I would just add to Mike that as you said, we are working very closely together. For example, while obviously we're not gonna provide color today on specific counties and the extent to which counties will exit, we wouldn't do that in an Oak Street footprint, as an example, right? So we're gonna be very thoughtful about how we trim our book with the goal of over time retaining the margins and attaining the margins that Tom articulated. I'd also remind you that every 100 basis points is worth more than $500 million on a trend basis. And so if you think about where historical trends have been, you think about where trends are today, we're in no way baking this in to our assumptions. But as you think about recovery here, this has the potential to bounce back and re-retain those, back to that profitability as well, which I think is important to mention. But we're gonna be very thoughtful about how we think about our membership footprint. Again, the ultimate goal is membership stability, but we're gonna favor margin over membership for next year. Our next question comes from Elizabeth Anderson of Evercore ISI. Elizabeth, please go ahead. Hi, guys. Good morning. Thanks for the question. I was just wondering, can you talk about sort of care management tools and sort of the impact that you're thinking about in terms of their impact on 2024, and then any sort of changes you're making in 2024 that you think will have an impact as we think about the 2025 results for HCB? Thank you. Well, clearly, care management is an important tool that we use to engage our members. And, you know, we spend a lot of time sort of segmenting who our high-risk members are, who are the members who would benefit most from care management. We're actually using a lot of really advanced AI tools to identify those members. We really think we have excellent analytics to be able to pinpoint who those members are and how are we best able to engage with them, what are the types of things that will get them to engage with us, and then also make it easier for our care management nurses at the point of care to be able to provide the level of advice and support that a member needs. And so it's something that we're very focused on. I would tell you that we continue to roll out some of these, these AI capabilities that makes these programs much more effective with much better ROIs. And so while there will be modest impacts in 2024, over time, we expect that to be a differentiator for us. And so we're very focused there. Yeah, I would just add to that. This is where the partnership between Health Care Delivery and Aetna comes in. Between Signify and some of the capabilities we have at Oak Street, there's a lot of boots on the ground in market capabilities that we have to really change the health trajectory of patients, whether that be readmissions to the hospital or managing your most complex chronic patients. And so this is where I think a lot of that partnership plays out, is in that space of getting a deeper level of impact, because we have the resources, we have the programs, we have the know-how. Now we can extend those over a lot more members. And so I think both Signify and Oak Street will bring a lot to the table over the coming years on how we can really bend that cost trend. Our final question comes from Ann Hynes of Mizuho Securities. Ann, please go ahead. Great, thanks. You talked about pharmacy services. There was some pressure on mix and also your inability to make prior guarantees. Can you just elaborate on both comments? And is the prior guarantee a diabetes issue, given the GLP-1 class? Thanks. It's not a diabetes issue. Think of it as, you know, the. We have to have projections about what the mix looks like to ensure that we appropriately hit all of our client guarantees. And with the changing mix inside the the quarter, given some of the disruptions that we saw, not only with the loss of a large client, but with the insourcing of another client's business and some of the disruptions in the marketplace in terms of volumes, specifically GLP-1s was part of that, we missed our guarantees by a little bit. We'll see how we're able to recoup that over the remainder of the year. But at this point, what we've assumed is that that first quarter is permanent, and that we can get back to our previous projections for the remainder of the year. David, anything you'd add to that? No, I think that's consistent with the way we see it. I will just add one thing on GLP-1s. Obviously, there's been a lot of volatility, one, because of supply constraints that we've experienced, and obviously, a lot of work around managing what we would see as this unprecedented demand, you know, combined with a very challenging price point, is leading to a lot of energy around how to best manage this category, through whether it be formulary, more aggressive utilization management, and then the broader care management wrappers on this. But this category alone is driving obviously significant costs for our clients, and it's also driving significant expense within our organization just to support what is now one of our highest drivers of call volume around people trying to find access to the product and making sure that we get consistent supply in the market. So we believe we've got a really strong set of programs and services to manage the category. And we believe once there's competition and adequate supply, we'll be able to have more consistency around how we manage this category. As we close the call, I want to just take this opportunity to thank our colleagues for their many contributions, and we look forward to providing you updates throughout the year. Thank you for joining the call today. Ladies and gentlemen, this concludes today's call. Thank you for joining. You may now disconnect.